Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Biomarker Analysis of Neoadjuvant Intralesional Therapy in High Risk Early Melanoma

NCT04427306 is registered in ClinicalTrials.gov with University of California, Davis as lead sponsor.

NCT NCT04427306
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04427306 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Biomarker Analysis of Neoadjuvant Intralesional Therapy in High Risk Early Melanoma
Lead sponsor
University of California, Davis
Phase
Phase 2
Overall status
Suspended
Start date
May 21, 2020
Completion date
May 21, 2024
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma